Arcutis Biotherapeutics Inc 2022 SR
The report is Arcutis Biotherapeutics' inaugural ESG disclosure, highlighting its commitment to medical dermatology and patient access. It details the 2022 FDA approval of ZORYVE and the establishment of the Arcutis Cares patient assistance program. The company emphasizes diversity in clinical trials and its workforce, noting that 52% of employees are women and 41% are from non-white backgrounds. Reporting is aligned with SASB standards and UN SDGs 8 and 10. Furthermore, the report outlines sustainable office practices, such as using 100% recyclable packaging and offering incentives for low-emission sales vehicles.
Company: Arcutis Biotherapeutics Inc
Sector: Health Care
Country: United States
Year: 2022
Type: SR
Pages: 22
Arcutis Biotherapeutics Inc
ESG Report
The report is Arcutis Biotherapeutics' inaugural ESG disclosure, highlighting its commitment to medical dermatology and patient access. It details the 2022 FDA approval of ZORYVE and the establishment of the Arcutis Cares patient assistance program. The company emphasizes diversity in clinical trials and its workforce, noting that 52% of employees are women and 41% are from non-white backgrounds. Reporting is aligned with SASB standards and UN SDGs 8 and 10. Furthermore, the report outlines sustainable office practices, such as using 100% recyclable packaging and offering incentives for low-emission sales vehicles.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities